Steward Partners Investment Advisory’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Steward Partners Investment Advisory’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-88	Closed	-$5K	–	2326
2018 Q3	$5K	Hold	88	–	–	﹤0.01%	2152
2018 Q2	$6K	Hold	88	–	–	﹤0.01%	1952
2018 Q1	$5K	Hold	88	–	–	﹤0.01%	1823
2017 Q4	$7K	Hold	88	–	–	﹤0.01%	1446
2017 Q3	$10K	Hold	88	–	–	﹤0.01%	1118
2017 Q2	$10K	Buy	88 +50	+132%	+$6.21K	﹤0.01%	1050
2017 Q1	$4K	Buy	+38	New	+$4.98K	﹤0.01%	1199

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steward Partners Investment Advisory's BLCM Position: Q4 2018 in Review

Steward Partners Investment Advisory sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2018, closing a stake of 88 shares — an estimated $5K sold.

Steward Partners Investment Advisory first reported a position in BLCM in Q1 2017 and held it in 7 quarters. The position peaked at $10K in Q3 2017. 92 funds tracked by Wall St. Rank hold BLCM as of Q4 2018.

Steward Partners Investment Advisory reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Steward Partners Investment Advisory sold 88 Bellicum Pharmaceuticals, Inc. shares in Q4 2018, an estimated $5K.
Steward Partners Investment Advisory first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2017 and held it in 7 quarters.
Steward Partners Investment Advisory's Bellicum Pharmaceuticals, Inc. position peaked at $10K in Q3 2017.
92 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2018.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2018, filed 15 Jan 2019.